Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed with results

Key Signals

2 with results80% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (5)
P 1 (6)
P 2 (5)

Trial Status

Completed8
Unknown4
Recruiting4
Active Not Recruiting3
Terminated2

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT06465069Phase 1Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06238479Phase 1Active Not Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT05786716Phase 2Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT04561362Phase 1Active Not RecruitingPrimary

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

NCT06237920Phase 2Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT04442724Not ApplicableRecruiting

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT04576286Phase 2CompletedPrimary

Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder

NCT04811846Not ApplicableActive Not RecruitingPrimary

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

NCT03636256Phase 1Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NCT05946369Completed

Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer

NCT03785925Phase 2CompletedPrimary

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

NCT05429710UnknownPrimary

SOX2 & PDL1 Expression on Urinary Bladder Carcinoma

NCT03389438Phase 2TerminatedPrimary

Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma

NCT05097105UnknownPrimary

Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses

NCT04144270UnknownPrimary

The Importance of Muscle Function in Patients With Disseminated Bladder Cancer

NCT04029948Not ApplicableUnknownPrimary

Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours

NCT02952989Phase 1Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

NCT02966535Not ApplicableCompleted

The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial

NCT02857634CompletedPrimary

Confocal Microscopy Dual Band in the Management of Bladder Cancer

NCT02977143Not ApplicableCompleted

Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery

Scroll to load more

Research Network

Activity Timeline